Search

Search Constraints

You searched for: Author/Creator Tesseur, Ina

Search Results

1. [P2–211]: AMYLOID‐β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID‐POSITIVE VERSUS AMYLOID‐NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT‐RISK FOR AD POPULATION. (1st July 2017)

2. [P4–510]: [18F]THK‐5117‐PET AND [11C]PIB‐PET IMAGING IN IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH) IN RELATION TO CONFIRMED AMYLOID‐β PLAQUES AND TAU IN BRAIN BIOPSIES. (1st July 2017)

3. Concordance of CSF AD biomarkers between intraventricular and lumbar CSF in iNPH. (20th December 2022)

4. Design of a patient‐ and investigator‐blind, randomized, placebo‐controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer's disease: The TOGETHER Study, AH0003. (31st December 2021)

5. O1‐10‐05: Pharmacodynamics of the Oral Bace Inhibitor JNJ‐54861911 in Early Alzheimer's Disease. (1st July 2016)

7. P1‐257: LONGITUDINAL COMPARISON OF CSF BIOMARKERS OF NEURODEGENERATION IN PATIENTS WITH PROBABLE IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH). (1st July 2019)

8. P2‐011: Pharmacokinetic/Pharmacodynamic Modeling of CSF AB1‐40 Reduction in an Early Alzheimer's Disease Study of JNJ‐54861911, an Oral Bace1 Inhibitor. (1st July 2016)

9. P4‐159: Screening and Recruitment Experience When Using Biomarker‐Based Population Definition in Alzheimer's Disease Studies. (1st July 2016)

10. The Neurofilament Surveillance Project (NSP): A biomarker study to sample blood quarterly in familial frontotemporal lobar degeneration. (20th December 2022)